With postdoctoral and industrial training, Dr. Jogender Tushir-Singh, Ph.D. is a rare investigator in academic settings. Dr. Tushir-Singh carried out his graduate work at the University of Notre Dame (http://biology.nd.edu) under Dr. D’souza-Schorey, Dept. of Biological Sciences. He went on to do his postdoctoral research at Howard Hughes Medical Institute at University of Massachusetts Medical School, Department of Biochemistry, Molecular pharmacology, and Psychiatry with Dr. Phillip Zamore (an RNAi Pioneer, Howard Hughes Medical Investigator and Chair of RNA Therapeutics Institute, http://www.umassmed.edu/zamore/about-us/biography/.
Before joining the University of Virginia, Dr. Tushir-Singh held Senior Biology Investigator and principal scientist positions at Abbvie Inc., Boehringer-Ingelheim Inc. Pharmaceuticals. He worked closely with antibody engineering, bispecific antibodies, and antibody conjugates. In September 2015, Dr. Tushir-Singh returned to academia and took his first faculty position to start antibody engineering research in his laboratory of novel biologics at the University of Virginia, Biochemistry and Molecular Genetics. In Sept. 2021, his laboratory moved to the University of California Davis, Department of Medical Microbiology and Immunology. Dr. Tushir-Singh is an Early Career Investigator of Ovarian Cancer Academy and is supported by funding from the U.S Department of Defense (DoD) and National Cancer Institute (NCI, NIH).